{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:49:17Z","timestamp":1787741357512,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41581-022-00581-0","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T06:19:45Z","timestamp":1651817985000},"page":"415-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interferon blockade in lupus: effects on antiviral immunity"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-494X","authenticated-orcid":false,"given":"Stefanie","family":"Steiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"E208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, E208\u2013E219 (2019).","journal-title":"Lancet Rheumatol."},{"key":"581_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"581_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496\u2013506 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"581_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","volume":"14","author":"MK Crow","year":"2019","unstructured":"Crow, M. K., Olferiev, M. & Kirou, K. A. Type I interferons in autoimmune disease. Annu. Rev. Pathol. 14, 369\u2013393 (2019).","journal-title":"Annu. Rev. Pathol."},{"key":"581_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","volume":"20","author":"E Der","year":"2019","unstructured":"Der, E. et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 20, 915\u2013927 (2019).","journal-title":"Nat. Immunol."},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/ki.2010.71","volume":"77","author":"HJ Anders","year":"2010","unstructured":"Anders, H. J., Lichtnekert, J. & Allam, R. Interferon-alpha and -beta in kidney inflammation. Kidney Int. 77, 848\u2013854 (2010).","journal-title":"Kidney Int."},{"key":"581_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ajpath.2013.04.017","volume":"183","author":"A Migliorini","year":"2013","unstructured":"Migliorini, A. et al. The antiviral cytokines IFN-\u03b1 and IFN-\u03b2 modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am. J. Pathol. 183, 431\u2013440 (2013).","journal-title":"Am. J. Pathol."},{"key":"581_CR8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070\u20132080 (2021).","journal-title":"Lancet"},{"key":"581_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1681\/ASN.2021091257","volume":"33","author":"S Steiger","year":"2022","unstructured":"Steiger, S., Rossaint, J., Zarbock, A. & Anders, H. J. Secondary immunodeficiency related to kidney disease (SIDKD) \u2014 definition, unmet need, and mechanisms. J. Am. Soc. Nephrol. 33, 259\u2013278 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"581_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000574","volume":"9","author":"A Kwan","year":"2022","unstructured":"Kwan, A. et al. Herpes zoster in SLE: prevalence, incidence and risk factors. Lupus Sci. Med. 9, e000574 (2022).","journal-title":"Lupus Sci. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00581-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:47:10Z","timestamp":1733939230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00581-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1038\/s41581-022-00581-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"6 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.-J.A. has received consultancy fees from Bayer, Janssen, GSK, Novartis, Boehringer, AstraZeneca and PreviPharma. S.S. has received research funding from Eleva Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}